Richmond News Now

DelveInsight, a leading market research and consulting firm, announces the release of its latest report, “Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast–2036.” The report provides a comprehensive understanding of Idiopathic Pulmonary Fibrosis, including historical and forecasted epidemiology, current treatment practices, emerging therapies, market trends, market size, market share, competitive landscape, and future opportunities across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Key Takeaways from the Idiopathic Pulmonary Fibrosis Market

• The Idiopathic Pulmonary Fibrosis market size across the 7MM is expected to grow significantly during the forecast period 2022–2036.

• The total Idiopathic Pulmonary Fibrosis market size in the 7MM was estimated at approximately USD 3.3 billion in 2025 and is projected to exceed USD 7.0 billion by 2036.

• The United States accounted for the largest Idiopathic Pulmonary Fibrosis market share among the 7MM in 2025.

• In 2025, the total diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis across the 7MM were estimated at approximately 300,000 cases.

• The United States accounted for nearly 125,000 diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis in 2025.

• Japan represented one of the largest patient populations among the 7MM, with approximately 55,500 diagnosed prevalent cases in 2025.

• Increasing disease awareness and improvements in high-resolution computed tomography (HRCT) are contributing to earlier diagnosis and treatment initiation.

• Current treatment options remain limited, creating significant opportunities for innovative disease-modifying therapies.

• Leading Idiopathic Pulmonary Fibrosis companies include Bristol Myers Squibb, PureTech Health, Cumberland Pharmaceuticals, Genentech/Roche, United Therapeutics, Boehringer Ingelheim, and others.

• Promising Idiopathic Pulmonary Fibrosis therapies include Admilparant (BMS-986278), Deupirfenidone (LYT-100), NIKTIMVO (axatilimab-csfr), Buloxibutid (C21), and TYVASO (treprostinil).

Keen to know more about the market? Request our sample page at https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market

Key Factors Driving the Idiopathic Pulmonary Fibrosis Market

Rising Disease Prevalence and Improved Diagnosis

Increasing awareness among physicians, wider use of advanced imaging technologies, and improved diagnostic guidelines are leading to earlier identification of IPF patients. Enhanced screening and referral pathways are supporting growth in the diagnosed patient pool.

Growing Adoption of Antifibrotic Therapies

The availability of antifibrotic agents such as OFEV and ESBRIET has significantly improved disease management. Increasing physician confidence in these therapies continues to drive treatment adoption across major markets.

High Unmet Need for Disease-Modifying Treatments

Despite therapeutic advances, current treatments primarily slow disease progression rather than reverse fibrosis. The need for therapies capable of halting or reversing lung damage remains a key market driver.

Strong Emerging Pipeline

The development of novel therapies targeting fibrosis, inflammation, immune pathways, and lung remodeling mechanisms is expected to reshape the future Idiopathic Pulmonary Fibrosis treatment landscape and expand market opportunities.

Idiopathic Pulmonary Fibrosis Competitive Landscape

Several therapies are currently marketed for Idiopathic Pulmonary Fibrosis, including OFEV (nintedanib) and ESBRIET (pirfenidone), which remain the standard of care for slowing disease progression and preserving lung function.

The emerging Idiopathic Pulmonary Fibrosis pipeline includes promising therapies such as Admilparant (BMS-986278), Deupirfenidone (LYT-100), NIKTIMVO (axatilimab-csfr), Buloxibutid (C21), and TYVASO (treprostinil). These candidates target diverse pathways involved in fibrosis progression, inflammatory signaling, macrophage activation, and tissue remodeling, aiming to improve efficacy beyond currently available treatments.

As several late-stage programs advance toward potential commercialization, competition within the Idiopathic Pulmonary Fibrosis drug market is expected to intensify substantially during the forecast period.

Discover more about therapies set to grab major Idiopathic Pulmonary Fibrosis market share @ Idiopathic Pulmonary Fibrosis Treatment Landscape

Recent Developments in the Idiopathic Pulmonary Fibrosis Market

• Bristol Myers Squibb continues advancing Admilparant (BMS-986278) through late-stage clinical development for Idiopathic Pulmonary Fibrosis.

• PureTech Health continues development of Deupirfenidone (LYT-100) as a differentiated deuterated form of pirfenidone designed to improve tolerability and pharmacokinetics.

• United Therapeutics is evaluating TYVASO (treprostinil) across broader pulmonary fibrosis-related indications.

• Research evaluating NIKTIMVO (axatilimab-csfr) continues to explore macrophage-targeted approaches for fibrotic lung diseases.

• Multiple companies are expanding clinical programs focused on novel anti-fibrotic and disease-modifying strategies.

What is Idiopathic Pulmonary Fibrosis?

Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, and ultimately fatal interstitial lung disease characterized by irreversible scarring (fibrosis) of lung tissue. The disease leads to declining lung function, worsening respiratory symptoms, impaired oxygen exchange, and reduced quality of life. Although the exact cause remains unknown, factors such as aging, genetic susceptibility, environmental exposures, and abnormal wound-healing responses are believed to contribute to disease development.

Patients commonly experience progressive shortness of breath, chronic dry cough, fatigue, and exercise intolerance. Without effective intervention, IPF often progresses to respiratory failure and premature mortality.

Idiopathic Pulmonary Fibrosis Epidemiology Segmentation

The Idiopathic Pulmonary Fibrosis epidemiology section provides insights into historical and forecasted patient populations across the 7MM and includes:

• Total Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis

• Age-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis

• Gender-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis

• Severity-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis

• Treated Cases of Idiopathic Pulmonary Fibrosis

• Country-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis

Scope of the Idiopathic Pulmonary Fibrosis Market Report

• Therapeutic Assessment: Current and Emerging Idiopathic Pulmonary Fibrosis Therapies

• Idiopathic Pulmonary Fibrosis Market Dynamics: Market Drivers, Barriers, Opportunities, and Future Trends

• Key Companies: Bristol Myers Squibb, PureTech Health, Cumberland Pharmaceuticals, Genentech/Roche, United Therapeutics, Boehringer Ingelheim, and others

• Key Therapies: OFEV, ESBRIET, Admilparant, Deupirfenidone, NIKTIMVO, Buloxibutid, TYVASO, and others

• Competitive Intelligence Analysis: SWOT Analysis and Market Entry Strategies

• Idiopathic Pulmonary Fibrosis Market Size, Market Share, Treatment Trends, and Industry Outlook

• Unmet Needs, KOL Perspectives, Analyst Views, Market Access, and Reimbursement Assessment

To know more about Idiopathic Pulmonary Fibrosis companies working in the treatment market, visit @ Idiopathic Pulmonary Fibrosis Clinical Trials and Therapeutic AssessmentTable of Contents

• Idiopathic Pulmonary Fibrosis Market Report Introduction

• Executive Summary for Idiopathic Pulmonary Fibrosis

• SWOT Analysis of Idiopathic Pulmonary Fibrosis

• Idiopathic Pulmonary Fibrosis Patient Share (%) Overview at a Glance

• Idiopathic Pulmonary Fibrosis Market Overview at a Glance

• Idiopathic Pulmonary Fibrosis Disease Background and Overview

• Idiopathic Pulmonary Fibrosis Epidemiology and Patient Population

• Country-Specific Patient Population of Idiopathic Pulmonary Fibrosis

• Idiopathic Pulmonary Fibrosis Current Treatment and Medical Practices

• Idiopathic Pulmonary Fibrosis Unmet Needs

• Idiopathic Pulmonary Fibrosis Emerging Therapies

• Idiopathic Pulmonary Fibrosis Market Outlook

• Country-Wise Idiopathic Pulmonary Fibrosis Market Analysis (2022–2036)

• Idiopathic Pulmonary Fibrosis Market Access and Reimbursement

• Idiopathic Pulmonary Fibrosis Market Drivers

• Idiopathic Pulmonary Fibrosis Market Barriers

• Idiopathic Pulmonary Fibrosis Competitive Landscape

• Idiopathic Pulmonary Fibrosis Appendix

• Idiopathic Pulmonary Fibrosis Report Methodology

• DelveInsight Capabilities

• Disclaimer

• About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through its subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/